

## **Product** Data Sheet

## ZDLD13


Cat. No.: HY-115908 CAS No.: 2762278-95-3 Molecular Formula:  $C_{18}H_{14}N_4O$  Molecular Weight: 302.33

Target: CDK; Apoptosis

Pathway: Cell Cycle/DNA Damage; Apoptosis

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

Description	ZDLD13, a $\beta$ -carboline, is an orally active and selective CDK4/CycD3 inhibitor with an IC <sub>50</sub> value of 0.38 $\mu$ M. ZDLD13 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD13 shows significant tumor growth inhibition in HCT116 tumor xenograft model <sup>[1]</sup> .
IC <sub>50</sub> & Target	CDK4/CycD3 0.38 μM (IC <sub>50</sub> )

## **REFERENCES**

[1]. Deping Li, et al. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer. Bioorg Chem. 2022 Apr;121:105659.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors